Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks

Annals of Oncology

Volumn 12, Issue 5, 2001, Pages 627-631

  Alberts, S R ^a   Erlichman, C ^a   Sloan, J ^a   Okuno, S H ^a   Burch, P A ^a   Rubin, J ^a   Pitot, H C ^a   Goldherg, R M ^a   Adjei, A A ^a   Atherton, P J ^a   Kaufmann, S H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Deoxycytidine; Gemcitabine; Irinotecan; Phase I; Transitional cell carcinoma

Indexed keywords

GEMCITABINE; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0034993111     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011140818150     Document Type: Article

References (26)

1. Clinical, toxicological and pharmacological aspects of gemcitabine
2. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters
3. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
4. Gemcitabine: Pre-clinical pharmacology and mechanisms of action
5. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
6. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine
7. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
8. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
9. Clinical applications of the camptothecins
10. CPT-11: An original spectrum of clinical activity
11. Pharmacology of irinotecan
12. A model for the mechanism of human topoisomerase I
13. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
14. Mechanism of action of camptothecin
15. The current status of camptothecin analogues as antitumor agents
16. Comparison of topoisomerase I inhibition. DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
17. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model
18. An integrated system for monitoring reporting and analyzing phase I oncology clinical trials
19. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer
20. The role of gemcitabine in the treatment of other tumours
21. Phase I study of CPT-11 and gemcitabine in patients with solid tumors
22. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
23. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
24. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose